IR@PKUHSC  > 北京大学第一临床医学院
学科主题临床医学
Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo
Tan, Qiang1,2; Li, Jing2; Yin, Han-wei3; Wang, Li-hui2; Tang, Wan-chen2; Zhao, Fang2; Liu, Xin-min1; Zeng, Hui-hui2,4
关键词Ethaselen Thioredoxin Reductase Inhibitor Cisplatin Non-small Cell Lung Cancer Combination Chemotherapy Synergistic Effect
刊名INVESTIGATIONAL NEW DRUGS
2010-06-01
DOI10.1007/s10637-009-9235-7
28期:3页:205-215
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Oncology ; Pharmacology & Pharmacy
研究领域[WOS]Oncology ; Pharmacology & Pharmacy
关键词[WOS]LUNG-CANCER CELLS ; MAMMALIAN THIOREDOXIN ; POSSIBLE INVOLVEMENT ; CYCLE ARREST ; APOPTOSIS ; CARCINOMA ; DESIGN ; GROWTH ; LINES ; CIS-DIAMMINEDICHLOROPLATINUM(II)
英文摘要

Ethaselen (1, 2-[bis (1, 2-Benzisoselenazolone-3 (2H) -ketone)] ethane, BBSKE), as a novel organoselenium compound targeting thioredoxin reductase (TrxR), has been reported to inhibit tumor growth and TrxR activity in several human tumor cell lines. It has now entered Phase I clinical trails. Here we report the effects of ethaselen and cisplatin (cis-diamminedichloroplatinum II, DDP) combination therapy (ethaselen 36 mg/kg, i.g., o.d. x 10 d and cisplatin 1 mg/kg, i.p., single at day 0) on human A549-grafted nude mouse model (female, BALB/c nude mouse, n = 5, treatment after tumor volume reached 100 mm(3)). Compared to single drug administration (either ethaselen: 36 mg/kg, i.g., o.d. x 10 d or cisplatin: 1.0 mg/kg, i.p., single at day 0), the combination therapy showed significantly reduced tumor size (presumably due to a synergistic effect) and no obvious toxic damage (both in terms of body weight maintenance and liver/kidney damage). These results will be significant in the development of novel anti-tumoral therapeutic strategies directed to non-small cell lung cancer (NSCLC).

语种英语
WOS记录号WOS:000276430200001
引用统计
被引频次:30[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/50438
专题北京大学第一临床医学院
北京大学第一临床医学院_老年病内科
北京大学第三临床医学院_皮肤科
作者单位1.Peking Univ, Hosp 1, Beijing 100034, Peoples R China
2.Peking Univ, Sch Pharmaceut Sci, State Key Lab Nat & Biomimet Drugs, Beijing 100191, Peoples R China
3.Peking Univ, Coll Life Sci, Beijing 100075, Peoples R China
4.Peking Univ, Hlth Sci Ctr, Sch Pharmaceut Sci, Beijing 100191, Peoples R China
推荐引用方式
GB/T 7714
Tan, Qiang,Li, Jing,Yin, Han-wei,et al. Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo[J]. INVESTIGATIONAL NEW DRUGS,2010,28(3):205-215.
APA Tan, Qiang.,Li, Jing.,Yin, Han-wei.,Wang, Li-hui.,Tang, Wan-chen.,...&Zeng, Hui-hui.(2010).Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo.INVESTIGATIONAL NEW DRUGS,28(3),205-215.
MLA Tan, Qiang,et al."Augmented antitumor effects of combination therapy of cisplatin with ethaselen as a novel thioredoxin reductase inhibitor on human A549 cell in vivo".INVESTIGATIONAL NEW DRUGS 28.3(2010):205-215.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Tan, Qiang]的文章
[Li, Jing]的文章
[Yin, Han-wei]的文章
百度学术
百度学术中相似的文章
[Tan, Qiang]的文章
[Li, Jing]的文章
[Yin, Han-wei]的文章
必应学术
必应学术中相似的文章
[Tan, Qiang]的文章
[Li, Jing]的文章
[Yin, Han-wei]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。